We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

73 hedge funds and large institutions have $23.1M invested in Carisma Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.4% less ownership

Funds ownership: 1.11% → 0.71% (-0.4%)

10% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $1.45M

13% less funds holding

Funds holding: 84 → 73 (-11)

22% less capital invested

Capital invested by funds: $29.5M → $23.1M (-$6.48M)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

43% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 23

Holders
73
Holders Change
-11
Holders Change %
-13.1%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
13
Reduced
23
Closed
24
Calls
$1.31M
Puts
$1.45M
Net Calls
-$142K
Net Calls Change
+$46K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.53M
2
E
Ergoteles
New York
+$566K
3
Morgan Stanley
Morgan Stanley
New York
+$426K
4
PFMU
Privium Fund Management (UK)
United Kingdom
+$190K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$97.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$5.32M
2
N
Nuveen
North Carolina
-$3.11M
3
State Street
State Street
Massachusetts
-$2.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.12M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWS
26
AJ Wealth Strategies
New York
$66K +$1.2K +105 +3%
Parallax Volatility Advisers
27
Parallax Volatility Advisers
California
$59K – – –
Charles Schwab
28
Charles Schwab
California
$56K -$256K -22,389 -87%
VVP
29
Venture Visionary Partners
Ohio
$53K – – –
Commonwealth Equity Services
30
Commonwealth Equity Services
Massachusetts
$40K -$23 -2 -0.1%
BFM
31
Boothbay Fund Management
New York
$37K +$26K +2,274 New
TSS
32
Two Sigma Securities
New York
$32K +$12.9K +1,125 +130%
LPL Financial
33
LPL Financial
California
$27K +$1.77K +155 +10%
Balyasny Asset Management
34
Balyasny Asset Management
Illinois
$27K +$19.4K +1,694 New
Osaic Holdings
35
Osaic Holdings
Arizona
$25K -$23 -2 -0.1%
WA
36
WealthTrust Axiom
Pennsylvania
$25K – – –
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$24.4K -$8.79K -768 -34%
OFG
38
Oxford Financial Group
Indiana
$24K – – –
YIH
39
Y-Intercept (HK)
Hong Kong
$24K +$17.2K +1,504 New
Victory Capital Management
40
Victory Capital Management
Texas
$21K -$103 -9 -0.7%
Mercer Global Advisors
41
Mercer Global Advisors
Colorado
$19K +$572 +50 +5%
FT
42
Fiduciary Trust
Massachusetts
$17K – – –
DC
43
Diametric Capital
Massachusetts
$17K +$11.8K +1,027 New
IWC
44
Integrated Wealth Concepts
Massachusetts
$16K – – –
IAG
45
Investment Advisory Group
Massachusetts
$16K – – –
PCS
46
Personal CFO Solutions
New Jersey
$15K – – –
CSS
47
Cubist Systematic Strategies
Connecticut
$15K +$10.6K +923 New
ProShare Advisors
48
ProShare Advisors
Maryland
$13K -$24.5K -2,142 -73%
Wolverine Trading
49
Wolverine Trading
Illinois
$13K +$9.59K +838 New
SG
50
StoneX Group
New York
$12.1K +$8.53K +745 New
1
2
3 4

CARM Hedge Fund Activity: Q2 2022 in Review

73 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2022, worth a combined $23.1M — down 22% from $29.5M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of CARM and 15 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 13 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.53M. The largest seller was BlackRock, cutting an estimated $5.32M.

  • 73 institutional investors held Carisma Therapeutics (CARM) as of Q2 2022, down from 84 in Q1 2022.
  • Funds reported $23.1M of Carisma Therapeutics stock for Q2 2022, down 22% quarter-over-quarter.
  • 15 funds opened new Carisma Therapeutics positions in Q2 2022 and 24 closed out, a net change of -9 holders.
  • The largest Carisma Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $1.53M added.
  • The largest Carisma Therapeutics seller in Q2 2022 was BlackRock, an estimated $5.32M sold.

Based on aggregated 13F filings for Q2 2022.